Intravitreal Ranibizumab Versus Aflibercept for Diabetic Macular Edema in Vitrectomized Eyes: 12 Month Results

• Published in: Seminars in ophthalmology 2021-11, Vol.36 (8), p.723-727
• Main Authors: Türkseven Kumral, Esra, Erçalık, Nimet Yeşim
• Format: Article
• Language: English
• Subjects: Aflibercept; Aged; Angiogenesis Inhibitors - therapeutic use; central macular thickness; Diabetes Mellitus; Diabetic Retinopathy - diagnosis; Diabetic Retinopathy - drug therapy; Female; Humans; injection frequency; Intravitreal Injections; Macular Edema - diagnosis; Macular Edema - drug therapy; Macular Edema - etiology; Male; Middle Aged; ranibizumab; Ranibizumab - therapeutic use; Receptors, Vascular Endothelial Growth Factor - therapeutic use; Recombinant Fusion Proteins - therapeutic use; Retrospective Studies; Tomography, Optical Coherence; Treatment Outcome; vitrectomy
• ISSN: 0882-0538; 1744-5205
• DOI: 10.1080/08820538.2021.1900287

To evaluate and compare the effect of intravitreal ranibizumab and aflibercept on the treatment of diabetic macular edema in previously vitrectomized eyes. A total of fifty-two vitrectomized eyes with diabetic macular edema were retrospectively evaluated. Patients were divided into two groups; Group 1 (n = 30 eyes) received 0.5 mg/0.05 mL intravitreal ranibizumab and Group 2 (n = 22 eyes) received 2 mg/0.05 mL intravitreal aflibercept for 3 monthly injections and thereafter as needed over 12 months. Best-corrected visual acuity (BCVA), central macular thickness (CMT) and injection number of the drugs were the outcomes of the study. Fifty-two previously vitrectomized eyes were enrolled in this study. Thirty-eight of them (73.1%) were male and 14 (26.9%) were female. The mean age was 61.54 ± 7.33 year (range: 50-72 year). BCVA increased and CMT decreased significantly in both groups at the end of the follow-up period (p  .05). However, there was a statistically significant difference between the groups in terms of the injection number (p